Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-1.14% $1.730
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 113.97 mill |
EPS: | -1.980 |
P/E: | -0.870 |
Earnings Date: | May 13, 2024 |
SharesOutstanding: | 65.88 mill |
Avg Daily Volume: | 0.143 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.870 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.15x |
Company: PE -0.870 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$3.23 (86.79%) $1.501 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 1.580 - 1.880 ( +/- 8.67%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | Zocca Mai-britt | Buy | 750 000 | Stock Option (Right to Buy) |
2024-03-15 | Sullivan Amy | Buy | 280 000 | Stock Option (Right to Buy) |
2024-03-15 | Smith Devin Whittemore | Buy | 185 000 | Stock Option (Right to Buy) |
2024-03-15 | Burkavage Brian | Buy | 50 000 | Stock Option (Right to Buy) |
2024-03-15 | Ahmad Qasim Iftikhar | Buy | 280 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
96.17 |
Last 87 transactions |
Buy: 67 695 200 | Sell: 7 604 578 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.730 (-1.14% ) |
Volume | 0.0535 mill |
Avg. Vol. | 0.143 mill |
% of Avg. Vol | 37.29 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.